|
1
|
Ghouri YA, Mian I and Blechacz B: Cancer
review: Cholangiocarcinoma. J Carcinog. 14:12015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sonakul D, Koompirochana C, Chinda K and
Stitnimakarn T: Hepatic carcinoma with opisthorchiasis. Southeast
Asian J Trop Med Public Health. 9:215–219. 1978.PubMed/NCBI
|
|
3
|
Björnsson E, Kilander A and Olsson R: CA
19-9 and CEA are unreliable markers for cholangiocarcinoma in
patients with primary sclerosing cholangitis. Liver. 19:501–508.
1999. View Article : Google Scholar
|
|
4
|
Qin XL, Wang ZR, Shi JS, Lu M, Wang L and
He QR: Utility of serum CA19-9 in diagnosis of cholangiocarcinoma:
In comparison with CEA. World J Gastroenterol. 10:427–432.
2004.PubMed/NCBI
|
|
5
|
Lumachi F, Lo Re G, Tozzoli R, D'Aurizio
F, Facomer F, Chiara GB and Basso SM: Measurement of serum
carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19
fragment and matrix metalloproteinase-7 for detecting
cholangiocarcinoma: A preliminary case-control study. Anticancer
Res. 34:6663–6667. 2014.PubMed/NCBI
|
|
6
|
Shigehara K, Yokomuro S, Ishibashi O,
Mizuguchi Y, Arima Y, Kawahigashi Y, Kanda T, Akagi I, Tajiri T,
Yoshida H, et al: Real-time PCR-based analysis of the human bile
microRNAome identifies miR-9 as a potential diagnostic biomarker
for biliary tract cancer. PLoS One. 6:e235842011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mott JL and Gores GJ: Targeting IL-6 in
cholangiocarcinoma therapy. Am J Gastroenterol. 102:2171–2172.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shen J, Wang W, Wu J, Feng B, Chen W, Wang
M, Tang J, Wang F, Cheng F, Pu L, et al: Comparative proteomic
profiling of human bile reveals SSP411 as a novel biomarker of
cholangiocarcinoma. PLoS One. 7:e474762012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang YH, Wu CC, Chang KP, Yu JS, Chang YC
and Liao PC: Cell secretome analysis using hollow fiber culture
system leads to the discovery of CLIC1 protein as a novel plasma
marker for nasopharyngeal carcinoma. J Proteome Res. 8:5465–5474.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Srisomsap C, Sawangareetrakul P,
Subhasitanont P, Chokchaichamnankit D, Chiablaem K, Bhudhisawasdi
V, Wongkham S and Svasti J: Proteomic studies of cholangiocarcinoma
and hepatocellular carcinoma cell secretomes. J Biomed Biotechnol.
2010:4371432010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tit-Oon P, Chokchaichamnankit D,
Khongmanee A, Sawangareetrakul P, Svasti J and Srisomsap C:
Comparative secretome analysis of cholangiocarcinoma cell line in
three-dimensional culture. Int J Oncol. 45:2108–2116.
2014.PubMed/NCBI
|
|
12
|
Weeraphan C, Diskul-Na-Ayudthaya P,
Chiablaem K, Khongmanee A, Chokchaichamnankit D, Subhasitanont P,
Svasti J and Srisomsap C: Effective enrichment of
cholangiocarcinoma secretomes using the hollow fiber bioreactor
culture system. Talanta. 99:294–301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Unno M, Mizushima T, Morimoto Y, Tomisugi
Y, Tanaka K, Yasuoka N and Tsukihara T: The structure of the
mammalian 20S proteasome at 2.75 A resolution. Structure.
10:609–618. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vangala JR, Dudem S, Jain N and Kalivendi
SV: Regulation of PSMB5 protein and β subunits of mammalian
proteasome by constitutively activated signal transducer and
activator of transcription 3 (STAT3): Potential role in
bortezomib-mediated anticancer therapy. J Biol Chem.
289:12612–12622. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen L and Madura K: Increased proteasome
activity, ubiquitin-conjugating enzymes, and eEF1A translation
factor detected in breast cancer tissue. Cancer Res. 65:5599–5606.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bazzaro M, Lee MK, Zoso A, Stirling WL,
Santillan A, Shih IeM and Roden RB: Ubiquitin-proteasome system
stress sensitizes ovarian cancer to proteasome inhibitor-induced
apoptosis. Cancer Res. 66:3754–3763. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sixt SU and Dahlmann B: Extracellular,
circulating proteasomes and ubiquitin - incidence and relevance.
Biochim Biophys Acta. 1782:817–823. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stoebner PE, Lavabre-Bertrand T, Henry L,
Guiraud I, Carillo S, Dandurand M, Joujoux JM, Bureau JP and
Meunier L: High plasma proteasome levels are detected in patients
with metastatic malignant melanoma. Br J Dermatol. 152:948–953.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sirisinha S, Tengchaisri T, Boonpucknavig
S, Prempracha N, Ratanarapee S and Pausawasdi A: Establishment and
characterization of a cholangiocarcinoma cell line from a Thai
patient with intrahepatic bile duct cancer. Asian Pac J Allergy
Immunol. 9:153–157. 1991.PubMed/NCBI
|
|
20
|
Laohathai K and Bhamarapravati N:
Culturing of human hepatocellular carcinoma. A simple and
reproducible method Am J Pathol. 118:203–208. 1985.
|
|
21
|
Srisomsap C, Sawangareetrakul P,
Subhasitanont P, Panichakul T, Keeratichamroen S, Lirdprapamongkol
K, Chokchaichamnankit D, Sirisinha S and Svasti J: Proteomic
analysis of cholangiocarcinoma cell line. Proteomics. 4:1135–1144.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iuga C, Seicean A, Iancu C, Buiga R, Sappa
PK, Völker U and Hammer E: Proteomic identification of potential
prognostic biomarkers in resectable pancreatic ductal
adenocarcinoma. Proteomics. 14:945–955. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanehisa M, Sato Y, Kawashima M, Furumichi
M and Tanabe M: KEGG as a reference resource for gene and protein
annotation. Nucleic Acids Res. 44D:D457–D462. 2016. View Article : Google Scholar
|
|
24
|
Tong Z, Kunnumakkara AB, Wang H, Matsuo Y,
Diagaradjane P, Harikumar KB, Ramachandran V, Sung B, Chakraborty
A, Bresalier RS, et al: Neutrophil gelatinase-associated lipocalin:
A novel suppressor of invasion and angiogenesis in pancreatic
cancer. Cancer Res. 68:6100–6108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lim R, Ahmed N, Borregaard N, Riley C,
Wafai R, Thompson EW, Quinn MA and Rice GE: Neutrophil
gelatinase-associated lipocalin (NGAL) an early-screening biomarker
for ovarian cancer: NGAL is associated with epidermal growth
factor-induced epithelia-mesenchymal transition. Int J Cancer.
120:2426–2434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fung KY, Priebe I, Purins L, Tabor B,
Brierley GV, Lockett T, Nice E, Gibbs P, Tie J, McMurrick P, et al:
Performance of serum lipocalin 2 as a diagnostic marker for
colorectal cancer. Cancer Biomark. 13:75–79. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chiang KC, Yeh TS, Wu RC, Pang JS, Cheng
CT, Wang SY, Juang HH and Yeh CN: Lipocalin 2 (LCN2) is a promising
target for cholangiocarcinoma treatment and bile LCN2 level is a
potential cholangiocarcinoma diagnostic marker. Sci Rep.
6:361382016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mukai C, Gao L, Bergkvist M, Nelson JL,
Hinchman MM and Travis AJ: Biomimicry enhances sequential reactions
of tethered glycolytic enzymes, TPI and GAPDHS. PLoS One.
8:e614342013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thongwatchara P, Promwikor n W, Srisomsap
C, Chokchaichamnankit D, Boonyaphiphat P and Thongsuksai P:
Differential protein expression in primary breast cancer and
matched axillary node metastasis. Oncol Rep. 26:185–191.
2011.PubMed/NCBI
|
|
30
|
Yoshida A, Okamoto N, Tozawa-Ono A,
Koizumi H, Kiguchi K, Ishizuka B, Kumai T and Suzuki N: Proteomic
analysis of differential protein expression by brain metastases of
gynecological malignancies. Hum Cell. 26:56–66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kang HJ, Jung SK, Kim SJ and Chung SJ:
Structure of human alpha-enolase (hENO1), a multifunctional
glycolytic enzyme. Acta Crystallogr D Biol Crystallogr. 64:651–657.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He P, Naka T, Serada S, Fujimoto M, Tanaka
T, Hashimoto S, Shima Y, Yamadori T, Suzuki H, Hirashima T, et al:
Proteomics-based identification of alpha-enolase as a tumor antigen
in non-small lung cancer. Cancer Sci. 98:1234–1240. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cappello P, Rolla S, Chiarle R, Principe
M, Cavallo F, Perconti G, Feo S, Giovarelli M and Novelli F:
Vaccination with ENO1 DNA prolongs survival of genetically
engineered mice with pancreatic cancer. Gastroenterology.
144:1098–1106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wygrecka M, Marsh LM, Morty RE, Henneke I,
Guenther A, Lohmeyer J, Markart P and Preissner KT: Enolase-1
promotes plasminogen-mediated recruitment of monocytes to the
acutely inflamed lung. Blood. 113:5588–5598. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fu QF, Liu Y, Fan Y, Hua SN, Qu HY, Dong
SW, Li RL, Zhao MY, Zhen Y, Yu XL, et al: Alpha-enolase promotes
cell glycolysis, growth, migration, and invasion in non-small cell
lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol.
8:222015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Capello M, Ferri-Borgogno S, Cappello P
and Novelli F: α-Enolase: A promising therapeutic and diagnostic
tumor target. FEBS J. 278:1064–1074. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yonglitthipagon P, Pairojkul C,
Bhudhisawasdi V, Mulvenna J, Loukas A and Sripa B: Proteomics-based
identification of α-enolase as a potential prognostic marker in
cholangiocarcinoma. Clin Biochem. 45:827–834. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Freeman AK and Morrison DK: 14-3-3
Proteins: Diverse functions in cell proliferation and cancer
progression. Semin Cell Dev Biol. 22:681–687. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Perathoner A, Pirkebner D, Brandacher G,
Spizzo G, Stadlmann S, Obrist P, Margreiter R and Amberger A:
14-3-3sigma expression is an independent prognostic parameter for
poor survival in colorectal carcinoma patients. Clin Cancer Res.
11:3274–3279. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu YJ, Jan YJ, Ko BS, Liang SM and Liou
JY: Involvement of 14-3-3 proteins in regulating tumor progression
of hepatocellular carcinoma. Cancers (Basel). 7:1022–1036. 2015.
View Article : Google Scholar
|
|
41
|
Khongmanee A, Lirdprapamongkol K, Tit-oon
P, Chokchaichamnankit D, Svasti J and Srisomsap C: Proteomic
analysis reveals important role of 14-3-3σ in anoikis resistance of
cholangiocarcinoma cells. Proteomics. 13:3157–3166. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Latham MP, Sekhar A and Kay LE:
Understanding the mechanism of proteasome 20S core particle gating.
Proc Natl Acad Sci USA. 111:5532–5537. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lavabre-Bertrand T, Henry L, Carillo S,
Guiraud I, Ouali A, Dutaud D, Aubry L, Rossi JF and Bureau JP:
Plasma proteasome level is a potential marker in patients with
solid tumors and hemopoietic malignancies. Cancer. 92:2493–2500.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jakob C, Egerer K, Liebisch P, Türkmen S,
Zavrski I, Kuckelkorn U, Heider U, Kaiser M, Fleissner C, Sterz J,
et al: Circulating proteasome levels are an independent prognostic
factor for survival in multiple myeloma. Blood. 109:2100–2105.
2007. View Article : Google Scholar
|
